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Abstract:
Background:
Iranian population is highly immune from T.Gondii and CMV infection.
Objective:
To determine the immunity to T.Gondii and CMV in children with the cochlear implant surgery accompanied with the profound Idiopathic type of
SNHL
Methods and Materials:
We studied 45 cases with the cochlear implant surgery (Idiopathic profound SNHL) and 30 controls with the normal OAEs in a cross-sectional
study in Rasoul Akram Hospital in Tehran (2010 -2012). Blood samples (2 ml) were centrifuged and were kept frozen at -20°C. Sera searched for
the specific antibodies against CMV and T.Gondii. The enzyme-linked immunosorbent assay (ELISA; BioChem Immune System) was calculated
qualitatively. (P value< 0.05)
Results:
Range of age in cases with profound SNHL (<95 dB) was 6 months- to-14 years; mean=3.4+3.16 y; Idiopathic type of SNHL children diagnosed in
45 cases were younger than cases with non-Idiopathic SNHL (mean age=20 months;  PV=0.05).  Positive T.Gondii  -  IgM was found in 8 /45
(17.7%) and also one of these cases (2.2%) had positive T.Gondii –IgG test. Positive CMV- IgM & IgG were determined in 23% and 51% of cases,
respectively. Positive T.Gondii –IgG was observed in 60% (18/30) of controls but none of them had positive T.Gondii – IgM. Positive CMV- IgM
& IgG in controls was 3.3% and 90%, respectively.
Conclusion:
CMV infection is one of the most common infections found in profound idiopathic SNHL children especially in younger cases (< 2 years) even in
highly immune Iranian populations. Probably, T.Gondii infection has a relative role in younger cases with profound SNHL but a higher role in mild
to moderate SNHL in our pediatric population. Most of the T.Gondii infected SNHL cases never require cochlear implant surgery.
In future, a cohort study for prenatal diagnosis of the intrauterine infection and the role of infection in producing SNHLwould be very helpful. It
has been recommended to search the specific antibodies against these two common infections in all types of SNHL in pediatric groups which are
treatable especially in younger cases (<2 year).
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1. INTRODUCTION
Sensor Neural Hearing Loss (SNHL) is a type of hearing
loss in which the root cause lies in the vestibulocochlear nerve
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(cranial  nerve  VIII),  the  inner  ear  or  the  central  processing
centres of the brain [1]. The ethology of SNHL is unknown in
near about 40% of children which may be viral in origin [1].
Idiopathic (unexplained) hearing loss may be the result of an
infectious disease or an injury [1]. Cytomegalovirus is the most
common cause  of  congenital  infection,  40% of  the  unknown
cause  of  deafness  cases  are  due  to  congenital  CMV  [2].
46   The Open Neurology Journal, 2019, Volume 13 Noorbakhsh et al.
Gancyclovir  treatment  is  recommended  for  diminishing  the
SNHL-induced congenital CMV [3, 4]. Asymptomatic infected
neonates might have SNHL, vision loss and mental retardation
and development delay [3, 4].
Many studies proved the significant role for the congenital
CMV in children with SNHL [2 -  4].  Yamamoto et  al.,  con-
firmed the prominent role for the congenital CMV in children
with  SNHL even  in  a  country  with  high  immunity  to  CMV.
They determined the rate, risk factors, and predictors of SNHL
in CMV-infected neonates identified by newborn screening in a
highly immune maternal population [4].
First  Siadati  et  al.,  reported  the  CMV  infection  in
primiparous  pregnant  women in  Tehran  [5].  Sotoodeh  et  al.,
described the CMV in South of Iran [6]. Bagheri et al., study
showed the seroprevalence of CMV infection (IgG and IgM)
among  240  pregnant  women  in  East  of  Iran  [7]  CMV  was
reported to  be  the  common cause  of  intrauterine  infection in
Iran [8, 9]. Congenital CMV infection was developed in 2.6%
of neonates in Tehran [9]. CMV infection was reported as one
of the most common infectious agents in SNHL children [10 -
12]
Congenital  toxoplasmosis  is  a  mild  or  severe  neonatal
disease  during  the  first  months  of  life,  or  with  sequels  or
relapse  of  a  previously  undiagnosed  infection  at  any  time
during infancy or later in life [13, 14]. 10-17% of infants with
congenital  toxoplasmosis  developed  SNHL  at  the  age  of  4
months or later [14, 15]. Treatment of Active T.Gondii infec-
tion in pregnant women can prevent congenital toxoplasmosis
from occurring in infants [16 - 20].
Screening for intrauterine infections during pregnancy or
in neonates is not available in Iran [21 - 23]. The prevalence of
antibodies to T.Gondii ranges from 24% to 57.7% in Iran [19,
20].  Acute  T-Gondii  was  reported  in  9.8%  of  TORCH  sus-
pected infants (< 2 y old) which had no significant difference
with controls but in contrast, the previous immunity was higher
in the control group [21].
All  the  above  studies  determined  that  the  adult  Iranian
population is highly immune to CMV infection. The burden of
congenital  CMV  associated  Sensor  Neural  Hearing  Loss
(SNHL)  in  populations  with  100%  CMV  seroprevalence  is
unknown [5].
Previous  immunity  from  T.Gondii  in  adult  Iranian
population  is  varied  between  24%-  57.7%  [19,  20]  which
causes  congenital  infection  in  about  10%  of  all  intrauterine
infection in our country. (21) CMV and T.Gondii infection may
play a major role in children with congenital or acquired forms
of SNHL in our country [10 - 12, 24, 25].
The main goal of study was to determine the immunity to
T.Gondii and CMV in children with cochlear implant surgery
(Idiopathic  SNHL;  <  95  db)  in  comparison  with  normal
children.
2. METHODS & MATERIALS
We studied that 117 children were diagnosed as profound
SNHL;  <  95  dB (according  to  AAO;  American  Academy of
Otolaryngology) criteria in cochlear implant center at Rasoul
Akram  Hospital  Tehran  in  the  duration  of  2  years  (2015  –
2017). This cross-sectional study was approved by the Ethical
Committee in Research Center of Pediatric Infectious Diseases
affiliated  with  Iran  University  of  Medical  Sciences.  The
consent  letter  was  obtained  from  all  persons  (or  parents).
2.1. Data Collection
All  children  with  profound  SNHL  were  referred  to  the
selected cochlear implant surgery department. From 117 cases
who were the candidates for cochlear implant surgery, 58.1%
were  male  and  49.1%were  female.  The  range  of  age  was:  6
months to 14 years; mean age =3.4+3.16. The Non-idiopathic
type  of  SNHL  (Infection,  familial,  kernicterus,  hypoxia,
prematurity, convulsion, mental retardation, malformation etc.)
was diagnosed in 39.5% of cases; Idiopathic type of SNHL was
determined  in  28.8%  (47/117)  of  cases.  Children  with
idiopathic type were younger than those in the cases with non-
Idiopathic (mean age=20 months; PV=0.05). The controls (n=
30)  had  normal  OAEs  in  screening  test  at  birth,  and  were
healthy  in  pediatrician  visit  before  elective  surgeries.  The
controls (n = 30) aged between 2-106 months, mean age = 38.7
- 27.3 months.
2.2. Lab Test
We  used  the  extra  blood  of  routine  tests  in  cases  and
controls.  Sera  was  kept  frozen  in  our  research  laboratory.  In
frozen  sera,  specific  antibodies  (IgG,  IgM)  against  CMV,  T.
Gondii  were  determined  by  Enzyme-linked  immunosorbent
assay  (Bio  Chem  Immune  Systems).  Antibodies  were  calcu-
lated qualitatively by cut-off controls according to the manu-
facturer’s instructions
2.3. Statistical Analysis
SPSS version 13 was used. All continuous variables eval-
uated by Student t -test. Chi-square values (CI: 95%; P<0.05)
were calculated. P value < 0.05 was significant.
3. RESULTS
Positive T.Gondii - IgM was found in 60% (18/30) of cases
and none of  the  controls  (0/30).  Positive  T.Gondii  –IgG was
detected in 2.2% (1/45) of cases and 60% (18/30) of controls.
Comparison of the serologic results between cases and controls
is showed in Table 1.  The correlation between age and sero-
logic results in cases showed in Table 2
4. DISCUSSION
Here, we studied 45 children with implant surgery due to
the Idiopathic type of SNHL. Cases with the Idiopathic SNHL
include  younger  children  than  non-Idiopathic  type  (mean
age=20 months). We observed recent CMV infection (positive
IgM)  in  23%  of  cases  (vs  3.3%  controls);  and  previous
immunity (positive IgG) in 51% of cases (vs. 90% controls).
Present findings are very close to other studies upon SNHL
children (and normal controls) in our center (11, 25); positive
CMV-IgM & IgG was observed in 23% of cases vs. 34.7% of
controls;  and  51%  of  cases  vs.  72.6%  controls,  respectively.
Recent CMV infection was higher in the SNHL cases (P-value
=  0.000)  but  previously,  there  was  higher immunity (CMV-
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Table 1. Comparison the serologic results between cases and controls.
– Age(Mean±SD) Positive Toxo- IgM Positive Toxo- IgG
Cases 20±3.47months 17% (8/45) 2.2% (1/45)
Normal Controls 38.73±27.3 months. none (0/30) 60% (18/30)
Age
(Mean±SD) Positive CMV- IgM Positive CMV- IgG
Cases 20±30.47 months 23% (11/45) 51% (23/45)
Normal Controls 38.73±27.3 months. 3.3% (1/30) %90% (27/30)
P value<0.05 considered significant
Table 2. Correlation of age and serologic results in cases.
Serologic results Mean age Value
Positive –Toxo IgM 4.7 months 0.5
Negative –Toxo IgM 5.8 months --
Positive –Toxo IgG 5.7 months 0.9
Negative –Toxo IgG 5.8 months --
IgG)  in  controls  (P  value  =  0.001).  Mean  age  of  cases  with
recent infection (positive IgM) was 40 months; and 35 months
for cases with previous immunity (positive IgG) probably due
to  the  transplacentel  immunity  which  waned  after  4  months
[11].  These  results  differ  from  the  previous  (2006-2008)
serological study in 11 idiopathic type of SNHL (mean age; 32
+28  months)  [12]  and  positive  CMV-  IgG in  100% of  cases
(previous immunity), none had recent infection (positive, IgM)
[12]
Yamamoto et al., described newborns with positive saliva
CMV-DNA in the first 2 weeks of life, a prospective follow-up
study was conducted to monitor hearing outcome [5]. Out of
12,195  infants  screened,  1% were  infected  with  CMV while
10% had a symptomatic infection at birth. SNHL was observed
in 9.8% in 12 months age.
Profound  SNHL  (>90  dB)  was  observed  in  4/5  children
with bilateral SNHL while all 5 children with unilateral SNHL
had moderate to severe loss [5]. Symptomatic CMV infection
is not related to intrauterine growth retardation, gestational age,
gravidity, and maternal age [5].
Some Iranian authors reported the seroprevalence of CMV
infection  in  Iranian  pregnant  women  [5  -  7].  Bagheri  et  al.,
described the seroprevalence of CMV (IgG and IgM) among
240 pregnant women in Eastern part. The IgG avidity test was
used for all patients who were CMV-IgM+ and CMV-IgG+ to
distinguish between primary and recurrent CMV infection [7].
All  CMV-  IgM+  were  monitored  until  labor.  The  CMV
seroprevalence  rate  was  72.1%,  69.6% had  a  previous  CMV
infection,  27.9%  had  never  been  infected  with  CMV,  2.5%
were CMV-IgM+,  1.66% had recurrent CMV infection (IgM+
and high IgG avidity) and 0.84% had primary CMV infection
(IgM+ and low IgG avidity) [7]. Indeed, CMV was reported to
be the common cause of  intrauterine infection in  Iran [8,  9].
Congenital CMV infection was developed in 2.6% of neonates
[9]
Here,  as  detailed  above,  the  rate  of  recent  T.Gondii
infection (IgM) was higher in the cases (17.7% vs.  0% cont-
rols); but in previous cases, the immunity (IgG) was very low
(2.2% vs. 60% controls). The previous immunity in the controls
(probably Trans placental  origin) might prevent the neonates
against  T.Gondii  intrauterine  infection.  The  present  study  is
very close to other reports in our country [22 - 24]. At least 2
studies confirm these results [22, 24].
The  study  to  search  the  congenital  toxoplasmosis  in  51
cases (mean age = 4.7 months + 3.7 month), and 30 controls in
our center had been published recently [22]. It showed recent
T.Gondii  infection  (IgM)  in  10%  of  cases  but  none  of  the
controls; previous immunity (IgG) was found in 18% cases and
60% of controls [22]. Like here, previous immunity (IgG) was
significantly  higher  in  the  control  healthy  group  (P  value
=0.00)  [22].  Similar  results  were  presented  in  our  previous
studies.  None  of  the  controls  were  detected  in  the  recent
T.Gondii  infection  (IgM)  in  comparison  with  12% of  SNHL
cases  (P  value  =0.00).  Previous  immunity  (IgG)  against
T.Gondii  infection  was  significantly  higher  in  the  control
healthy  group  (48%  vs.  21%;  P  value  <  0.001)  [24,  25].
All  results  confirmed  the  relative  role  for  T.Gondii  in
studied cases.(19,24) The rate of seropositivity in severe SNHL
which  is  4  fold  lower  than  the  previous  study  (63.6%)  had
applied  upon  all  type  of  SNHL in  our  center.  2.2% of  cases
with  severe  SNHL  had  recent  T.Gondii  infection  (vs.  10%
previous  study)  [24].  It  means  that  T.Gondii  infection  might
have a higher role in mild to moderate SNHL in our pediatric
population.  Most  of  the  infected  SNHL  cases  never  require
cochlear implant surgery.
The prevalence of T Gondii antibodies ranges from 24% to
57.7% in Iranian population [19, 20].One study determined the
previous and acute T Gondii  infection in 34.7% and 7.1% of
young  pregnant  women  in  Tehran  [19].  Recent  infection
observed  in  9.8%  of  TORCH  suspected  infants(<2y  old)  in
Tehran;  but  previous  immunity(positive  IgG)  was  higher  in
normal children [8]. So, the congenital toxoplasmosis can be
prevented  by  the  treatment  of  Active  T.Gondii  infection  in
pregnant  women  [13  -  15].  Treatment  of  congenital  toxo-
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plasmosis in the first year of life could prevent this late sequel
[16 - 20]. In our opinion, the neonatal screening test (Guthrie
cards) might be helpful to detect at least 2 common treatable
infections (; CMV / T.Gondii) in our country.
We observed recent CMV infection (positive IgM) in 23%
of cases (vs  3.3% controls); and previous immunity (positive
IgG) in 51% of cases (vs. 90% controls).
So, we recommend rapid diagnosis and suitable treatment
of  the  indolent  infections  in  SNHL  children  to  decrease  the
requirement of cochlear implantation surgery.
At  least  1-year  treatment  is  required  in  infants  (positive
IgM) for the prevention of its sequels [10, 13]
CONCLUSION
CMV infection is one of the most common infection found
in  profound  idiopathic  SNHL children  especially  in  younger
cases (< 2 years) even in highly immune Iranian populations.
Probably T.Gondii infection has a relative role in younger cases
with  profound  SNHL but  a  higher  role  in  mild  to  mode-rate
SNHL  in  our  pediatric  population.  Most  of  the  T.Gondii
infected SNHL cases never require cochlear implant surgery.
In  the  future,  a  cohort  study  for  prenatal  diagnosis  of
intrauterine  infection  and  the  role  of  infection  in  producing
SNHL  would  be  very  helpful.  We  recommend  to  search  the
specific antibodies against these two common infections in all
type  of  SNHL in  pediatric  groups,  which  are  treatable  espe-
cially in younger cases (< 2 year).
LIMITATIONS OF THE STUDY
This  study  followed  the  known  cases  of  SNHL  for
intrauterine infection after birth. This time of diagnosis is late
for specific treatment. In contrast to the developed countries,
the prenatal /perinatal screening for intrauterine infection is not
available  in  Iran.  We  should  diagnose  the  indolent  (intrau-
terine)  infections  in  SNHL children  and  treatment  should  be
started as soon as possible to decrease the need of the cochlear
implantation surgery
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